Mcl-1 Antagonists Promoting Bak Permeabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics targeting apoptotic signaling have limited effectiveness in treating cancer due to deregulation of apoptosis, with few compounds reaching clinical evaluation, and existing Mcl-1 inhibitors are not effective in promoting Bak-mediated permeabilization of liposomal membranes.
Innovation Solution
Development of pharmaceutical compositions containing specific compounds that antagonize Mcl-1 by binding to it, thereby stimulating Bak-mediated permeabilization of liposomal membranes and promoting cell death, including compounds with specific structural formulas that selectively target Mcl-1 over Bcl-2 or Bcl-xL.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Mcl-1 inhibitors are used, then some level of Mcl-1 antagonism is achieved, but they are not effective in promoting Bak-mediated permeabilization of liposomal membranes
Solution Approach 1:
The patent modifies chemical parameters of Mcl-1 inhibitor compounds by varying substituent groups (R1-R6) at specific positions on the core molecular structure. This systematic parameter optimization enables the compounds to effectively promote Bak-mediated permeabilization of liposomal membranes while maintaining manageable structural complexity.
Solution Approach 2:
The patent introduces specific substituent groups at localized positions (R1-R6) on the molecular structure to enhance specific functional properties. These localized modifications allow the compound to selectively antagonize Mcl-1 and promote Bak-mediated permeabilization without requiring complete structural redesign.
2Measurement precision
If compounds selectively target Mcl-1 over Bcl-2 or Bcl-xL are developed, then specificity in cancer treatment is improved, but manufacturing complexity increases
Solution Approach 1:
The patent achieves Mcl-1 selectivity by optimizing specific chemical parameters including substituent types (halogen, alkyl, aryl groups), their positions (R1-R6), and molecular configuration. These parameter optimizations provide selective Mcl-1 targeting while using established chemical synthesis methods that remain feasible for manufacturing.
Solution Approach 2:
The patent divides the molecular structure into a core scaffold with separate substituent positions (R1-R6), allowing independent optimization of each segment for selectivity. This modular approach enables systematic structure-activity relationship studies and facilitates synthesis planning.
Data Source
AI summary
Provided herein are Mcl-1 antagonist compositions and methods of treating cancer using the compositions described herein.